Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

305
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
305
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

176
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176
Pneumonia IV: Management01:28

Pneumonia IV: Management

438
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
438
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

30
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
30
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

19
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conversion of Poly(3-hydroxybutyrate) (PHB) bioplastics to short-chain fatty acids by acidogenic fermentation: Effect of inoculum to substrate ratio, PHB pre-treatment and operating temperature.

Enzyme and microbial technology·2026
Same author

Exploring the nexus between perceived organizational support and professional identity among nursing professionals: a mediation-moderation mechanism.

BMC nursing·2026
Same author

The Impact of Digital Healthcare Adoption and Service Quality on Patient Satisfaction: The Moderating Role of Telehealth Services in Pakistan.

Journal of nursing management·2026
Same author

Carbapenem-resistant Enterobacterales across the UK: a nationwide study of carbapenemase testing and novel antimicrobial activity.

International journal of antimicrobial agents·2026
Same author

Adolescent Grassroots Soccer and Sports-Related Concussion: A Program for Change.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine·2026
Same author

Biofilm Disruption and Gene Expression Alteration by Phages against Multi-Drug-Resistant Pseudomonas aeruginosa<i></i>.

Canadian journal of microbiology·2026

Related Experiment Video

Updated: Sep 5, 2025

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

525

mRNA-based modalities for infectious disease management.

Mengjie Zhang1, Abid Hussain1, Haiyin Yang1

  • 1School of Life Science, Advanced Research Institute of Multidisciplinary Science, School of Medical Technology (Institute of Engineering Medicine), Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, 100081 China.

Nano Research
|July 12, 2022
PubMed
Summary

Messenger RNA (mRNA) vaccines are revolutionizing infectious disease control, offering rapid development and adaptability. This technology shows great promise beyond COVID-19, addressing urgent global health needs.

Keywords:
coronavirus disease 2019 (COVID-19)drug deliveryinfectious diseaselipid-nanoparticlemessenger RNA (mRNA) vaccinevirus

More Related Videos

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

523
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.2K

Related Experiment Videos

Last Updated: Sep 5, 2025

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

525
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

523
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.2K

Area of Science:

  • Pharmaceutical Science
  • Vaccinology
  • Molecular Biology

Background:

  • The COVID-19 pandemic highlighted the urgent need for rapid vaccine development.
  • Messenger RNA (mRNA) technology has emerged as a powerful platform for vaccine creation.
  • The success of mRNA vaccines against COVID-19 has spurred research into their application for other infectious diseases.

Purpose of the Study:

  • To review the unique properties of mRNA-based vaccines for infectious diseases.
  • To discuss advancements in mRNA delivery technologies.
  • To explore the challenges and future prospects of mRNA therapeutics.

Main Methods:

  • Literature review of preclinical and clinical studies on mRNA therapeutics.
  • Analysis of mRNA vaccine properties and delivery systems.
  • Discussion of current challenges and future potential.

Main Results:

  • mRNA technology offers rapid response capabilities crucial for mutating viruses like Omicron.
  • mRNA vaccines have demonstrated efficacy and are being tested for various infectious diseases.
  • Delivery technologies are continuously improving for enhanced mRNA vaccine performance.

Conclusions:

  • mRNA-based vaccines represent a significant advancement in combating infectious diseases.
  • The adaptability of mRNA technology positions it as a key tool for future pandemic preparedness.
  • Continued research and development are essential to overcome current challenges and unlock the full potential of mRNA therapeutics.